STOCKHOLM, SWEDEN/ACCESSWIRE/May 13, 2022/ Promote Pharma (STO:PROMO)(FRA:8T0)
STOCKHOLM, May 13, 2022 – Promore Pharma AB (publ) publishes its interim report for the first quarter of 2022 on May 17, 2022.
On the same day, the company will host a webcast conference call at 4:00 p.m. CET, with Chairman and CEO Jonas Ekblom and Chief Financial Officer Erik Magnusson, where an update for the quarter and upcoming business. After the presentation, there will be a Q&A session. The conference call will be conducted in English and will be accessible via computer, tablet or phone.
The number of participants is limited, please register in advance for the conference on the following link:
https://attendee.gotowebinar.com/register/4045498425908535564
The conference call will be recorded and made available on the company’s website after the call, and on the Västra Hamnen Corporate Finance Youtube channel.
About Promore Pharma
Promore Pharma is a biopharmaceutical company developing drug candidates for the bioactive treatment of wounds. Today, the company has two drug candidates in advanced clinical development, based on endogenous peptides, and therefore endowed with a strong safety profile. Both of these products are intended for the treatment of chronic wounds and the prevention of scarring of the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.
For more information, please contact
Jonas Ekblom, CEO
Call: [+46] 736 777 540
Email: [email protected]
Erik Magnusson, Chief Financial Officer
Call: [+46] 708 565 245
Email: [email protected]
Promore Pharmas Certified Advisor is Erik Penser Bank
Such : [+46] 8-463 83 00
Email: [email protected]
Attachments
THE SOURCE: Promote Pharma
See the source version on accesswire.com:
https://www.accesswire.com/701250/Invitation-to-Conference-Call-Regarding-Promore-Pharmas-Interim-Report-for-the-First-Quarter-2022
